Gerald H.
Gerald H. Gorsegner, Jr., Denver, CO US
Patent application number | Description | Published |
---|---|---|
20100274896 | SYSTEMS AND METHODS FOR FLOW SIGNATURE FORMATION AND USE - An embodiment of a method for use in performing interoperability testing between two network architectures includes forming multiple transaction signatures that each characterizes a communication transaction conducted over the two networks and analyzing each of the transaction signatures to determine if the transaction signature matches a previously classified pattern. The method may further include generating a report identifying each of the communication transactions and indicating that each of the communication transactions is classified with a classification associated with a previously classified pattern or are of unknown classification. Another method includes receiving a transaction signature composed of multiple transaction elements, and determining whether the received transaction signature corresponds to a previously identified transaction signature pattern. If the transaction signature does not correspond to a previously identified transaction signature pattern, a new transaction signature pattern is created, and classified as one of a plurality of classifications indicative of completion or failure of the communication transaction. | 10-28-2010 |
Gerald H. Johnson, Andover, MN US
Patent application number | Description | Published |
---|---|---|
20100259277 | AUTOMATED TEST EQUIPMENT EMPLOYING TEST SIGNAL TRANSMISSION CHANNEL WITH EMBEDDED SERIES ISOLATION RESISTORS - Automated test equipment for high-speed testing of devices under test (DUTs) includes a tester channel circuit generating a high-speed electrical test signal applied to the signal input terminal of each DUT, and a contacter board in physical and electrical contact with the DUTs. The contacter board has a high-speed signal transmission channel including (1) an electrical contact at which the high-speed electrical test signal is received, (2) conductive etch extending from the electrical contact to isolation areas each adjacent to the signal input terminal of a respective DUT, and (3) an embedded series isolation resistor formed on an inner layer of the contacter board at a respective isolation area forming a connection between the conductive etch and the adjacent signal input terminal of the respective DUT. | 10-14-2010 |
20140361798 | CALIBRATION DEVICE - An example apparatus is for use in calibration of a test system having multiple channels and a socket for receiving a device under test. The example apparatus includes a device interface that is connectable to the socket; and multiple circuit paths, where each circuit path is connectable, through the device interface, to a corresponding channel of the test system and being connected to a common node. The example apparatus is configured so that, during calibration, signals either (i) each pass from the test system, through one of the multiple circuit paths, and back to the test system through others of the multiple circuit paths, or (ii) each pass from the test system, through the others of the multiple circuit paths, and back to the test system through the one of the multiple circuit paths. | 12-11-2014 |
Gerald H. Lushington, Lawrence, KS US
Patent application number | Description | Published |
---|---|---|
20090170842 | BRCA1-BASED BREAST OR OVARIAN CANCER PREVENTION AGENTS AND METHODS OF USE - A pharmaceutical composition for use in treating, inhibiting, and/or preventing breast and/or ovarian cancer can include: a molecule having a structure of one of Compounds 1-38, pharmaceutically acceptable salt thereof, or analog thereof, and a pharmaceutically acceptable carrier containing the compound. The pharmaceutically acceptable carrier can be configured for oral, systemic, transdermal, intranasal, suppository, parenteral, intramuscular, intravenous, or subcutaneous administration. The compound can be present in the composition in a therapeutically effective amount for treating, inhibiting, and/or preventing breast and/or ovarian cancer. Also, the compound can be present in a therapeutically effective amount for enhancing production of BRCA1. | 07-02-2009 |
20120259005 | BRCA1-Based Breast or Ovarian Cancer Prevention Agents and Methods of Use - A pharmaceutical composition for use in treating, inhibiting, and/or preventing breast and/or ovarian cancer can include: a molecule having a structure of one of Compounds 1-38, pharmaceutically acceptable salt thereof, or analog thereof; and a pharmaceutically acceptable carrier containing the compound. The pharmaceutically acceptable carrier can be configured for oral, systemic, transdermal, intranasal, suppository, parenteral, intramuscular, intravenous, or subcutaneous administration. The compound can be present in the composition in a therapeutically effective amount for treating, inhibiting, and/or preventing breast and/or ovarian cancer. Also, the compound can be present in a therapeutically effective amount for enhancing production of BRCA1. | 10-11-2012 |